2 results
Approved WMOPending
Evaluating the long term safety and tolerability of ranibizumab treatment of AMD patients.
Approved WMORecruiting
The primary objective of the study is to determine the efficacy of AP26113, as evidenced by objective response rate, in patients with ALK positive locally advanced or metastatic NSCLC whose disease has progressed on therapy with crizotinib.